"Peter J. Hotez and Maria Elena Bottazzi began development on the vaccine, known as CORBEVAX, in 2020 and currently are awaiting the final results of Phase Three clinical trials to determine its efficacy rate with respect to the Omicron COVID-19 variant.

In sharp contrast to the four dominant vaccines globally, CORBEVAX is protected by no patents or other intellectual property protection."

#RachelThrasher

https://www.bu.edu/gdp/2022/02/06/open-source-covid-19-vaccine-offers-potential-pathway-for-vaccinating-the-world/

#COVID #vaccines #CORBEVAX #DrugPatents